588 related articles for article (PubMed ID: 12135009)
1. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Papatheodoridis GV; Dimou E; Papadimitropoulos V
Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Ayres A; Bartholomeusz A; Lau G; Lam KC; Lee JY; Locarnini S
J Clin Virol; 2003 May; 27(1):111-6. PubMed ID: 12727536
[TBL] [Abstract][Full Text] [Related]
3. Current pharmacotherapy for the treatment of chronic hepatitis B.
Lagget M; Rizzetto M
Expert Opin Pharmacother; 2003 Oct; 4(10):1821-7. PubMed ID: 14521491
[TBL] [Abstract][Full Text] [Related]
4. Management of viral hepatitis B.
Pramoolsinsup C
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
[TBL] [Abstract][Full Text] [Related]
5. Clinical potential of emerging new agents in hepatitis B.
Farrell GC
Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis B.
Yuen MF; Lai CL
Lancet Infect Dis; 2001 Nov; 1(4):232-41. PubMed ID: 11871510
[TBL] [Abstract][Full Text] [Related]
7. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
9. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
10. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.
Wolters LM; Hansen BE; Niesters HG; de Man RA
Eur J Gastroenterol Hepatol; 2002 Sep; 14(9):1007-11. PubMed ID: 12352221
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside analogues for chronic hepatitis B.
Wolters LM; Niesters HG; de Man RA
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1499-506. PubMed ID: 11742201
[TBL] [Abstract][Full Text] [Related]
12. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
[TBL] [Abstract][Full Text] [Related]
13. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
14. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
15. HBV mutations associated with lamivudine therapy.
Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
[TBL] [Abstract][Full Text] [Related]
16. Chronic hepatitis B--treatment with nucleoside analogues.
Leung N
Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
[TBL] [Abstract][Full Text] [Related]
17. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
18. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.
Rizzetto M
J Med Virol; 2002 Apr; 66(4):435-51. PubMed ID: 11857520
[TBL] [Abstract][Full Text] [Related]
20. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]